Spyre Historical Financial Ratios

SYRE Stock   17.02  1.14  6.28%   
Spyre Therapeutics is promptly reporting on over 74 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.31, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 27.38 will help investors to properly organize and evaluate Spyre Therapeutics financial condition quickly.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

About Spyre Financial Ratios Analysis

Spyre TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Spyre Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Spyre financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Spyre Therapeutics history.

Spyre Therapeutics Financial Ratios Chart

At present, Spyre Therapeutics' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 27.38, whereas Book Value Per Share is forecasted to decline to 1.31.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Spyre Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Spyre Therapeutics sales, a figure that is much harder to manipulate than other Spyre Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.
Most ratios from Spyre Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 27.38, whereas Book Value Per Share is forecasted to decline to 1.31.
 2022 2024 2025 (projected)
Days Sales Outstanding58.7767.59107.38
PTB Ratio0.7516.8310.84

Spyre Therapeutics fundamentals Correlations

-0.25-0.05-0.320.070.55-0.47-0.250.960.560.360.330.24-0.32-0.26-0.610.6-0.61-0.38-0.470.29-0.6-0.60.33-0.61-0.24
-0.250.29-0.590.380.490.941.0-0.230.48-0.970.48-0.49-0.17-0.61-0.26-0.3-0.250.98-0.3-0.96-0.28-0.22-0.97-0.270.4
-0.050.290.020.140.150.30.29-0.150.15-0.240.23-0.250.35-0.04-0.17-0.01-0.160.320.09-0.23-0.16-0.16-0.23-0.160.17
-0.32-0.590.02-0.06-0.8-0.38-0.59-0.33-0.80.57-0.72-0.110.50.990.52-0.130.52-0.450.350.590.550.490.580.54-0.01
0.070.380.14-0.060.190.390.380.210.18-0.210.2-0.890.14-0.08-0.42-0.36-0.420.37-0.14-0.2-0.42-0.42-0.2-0.410.86
0.550.490.15-0.80.190.240.490.511.0-0.370.910.08-0.52-0.82-0.730.33-0.730.32-0.36-0.4-0.74-0.71-0.39-0.740.08
-0.470.940.3-0.380.390.240.94-0.430.23-0.940.27-0.58-0.02-0.41-0.03-0.57-0.020.97-0.19-0.92-0.040.01-0.93-0.030.43
-0.251.00.29-0.590.380.490.94-0.230.48-0.970.48-0.49-0.17-0.61-0.26-0.3-0.250.98-0.3-0.96-0.28-0.22-0.97-0.270.4
0.96-0.23-0.15-0.330.210.51-0.43-0.230.510.340.260.11-0.17-0.27-0.570.49-0.58-0.36-0.50.29-0.57-0.570.31-0.58-0.12
0.560.480.15-0.80.181.00.230.480.51-0.370.90.09-0.52-0.82-0.730.35-0.730.31-0.36-0.4-0.74-0.71-0.38-0.730.07
0.36-0.97-0.240.57-0.21-0.37-0.94-0.970.34-0.37-0.350.40.160.580.070.310.06-0.980.310.990.090.021.00.08-0.25
0.330.480.23-0.720.20.910.270.480.260.9-0.350.08-0.48-0.79-0.80.19-0.790.30.05-0.33-0.8-0.79-0.34-0.80.29
0.24-0.49-0.25-0.11-0.890.08-0.58-0.490.110.090.40.08-0.33-0.090.090.460.09-0.570.180.380.090.080.390.08-0.78
-0.32-0.170.350.50.14-0.52-0.02-0.17-0.17-0.520.16-0.48-0.330.490.33-0.190.33-0.040.150.190.330.330.170.330.21
-0.26-0.61-0.040.99-0.08-0.82-0.41-0.61-0.27-0.820.58-0.79-0.090.490.56-0.10.56-0.470.250.590.590.530.590.58-0.09
-0.61-0.26-0.170.52-0.42-0.73-0.03-0.26-0.57-0.730.07-0.80.090.330.56-0.31.0-0.090.00.061.01.00.061.0-0.44
0.6-0.3-0.01-0.13-0.360.33-0.57-0.30.490.350.310.190.46-0.19-0.1-0.3-0.3-0.37-0.240.28-0.29-0.290.3-0.3-0.45
-0.61-0.25-0.160.52-0.42-0.73-0.02-0.25-0.58-0.730.06-0.790.090.330.561.0-0.3-0.08-0.010.051.01.00.051.0-0.44
-0.380.980.32-0.450.370.320.970.98-0.360.31-0.980.3-0.57-0.04-0.47-0.09-0.37-0.08-0.29-0.96-0.11-0.05-0.97-0.10.39
-0.47-0.30.090.35-0.14-0.36-0.19-0.3-0.5-0.360.310.050.180.150.250.0-0.24-0.01-0.290.40.01-0.050.360.00.32
0.29-0.96-0.230.59-0.2-0.4-0.92-0.960.29-0.40.99-0.330.380.190.590.060.280.05-0.960.40.080.011.00.07-0.18
-0.6-0.28-0.160.55-0.42-0.74-0.04-0.28-0.57-0.740.09-0.80.090.330.591.0-0.291.0-0.110.010.081.00.081.0-0.44
-0.6-0.22-0.160.49-0.42-0.710.01-0.22-0.57-0.710.02-0.790.080.330.531.0-0.291.0-0.05-0.050.011.00.011.0-0.45
0.33-0.97-0.230.58-0.2-0.39-0.93-0.970.31-0.381.0-0.340.390.170.590.060.30.05-0.970.361.00.080.010.07-0.2
-0.61-0.27-0.160.54-0.41-0.74-0.03-0.27-0.58-0.730.08-0.80.080.330.581.0-0.31.0-0.10.00.071.01.00.07-0.43
-0.240.40.17-0.010.860.080.430.4-0.120.07-0.250.29-0.780.21-0.09-0.44-0.45-0.440.390.32-0.18-0.44-0.45-0.2-0.43
Click cells to compare fundamentals

Spyre Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(1.00)
Earnings Share
(3.18)
Return On Assets
(0.27)
Return On Equity
(0.59)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.